key: cord-0887382-pyaxnga9 authors: Guéant, Jean‐Louis; Guéant‐Rodriguez, Rosa‐Maria; Fromonot, Julien; Oussalah, Abderrahim; Louis, Huguette; Chery, Celine; Gette, Mickael; Gleye, Stanislas; Callet, Jonas; Raso, Jeremie; Blanchecotte, François; Lacolley, Patrick; Guieu, Régis; Regnault, Véronique title: Elastase and exacerbation of neutrophil innate immunity are involved in multi‐visceral manifestations of COVID‐19 date: 2021-02-27 journal: Allergy DOI: 10.1111/all.14746 sha: d34aab373d3a7dffb2e38234fe3cad4597d4921a doc_id: 887382 cord_uid: pyaxnga9 BACKGROUND: Many arguments suggest that neutrophils could play a prominent role in COVID‐19. However, the role of key components of neutrophil innate immunity in severe forms of COVID‐19 has deserved insufficient attention. We aimed to evaluate the involvement of neutrophil elastase, histone‐DNA, and DNases in systemic and multi‐organ manifestations of COVID‐19. METHODS: We performed a multicenter study of markers of neutrophil innate immunity in 155 cases consecutively recruited in a screening center, local hospitals, and two regional university hospitals. The cases were evaluated according to clinical and biological markers of severity and multi‐organ manifestations and compared to 35 healthy controls. RESULTS: Blood neutrophil elastase, histone‐DNA, myeloperoxidase‐DNA, and free dsDNA were dramatically increased, and DNase activity was decreased by 10‐fold, compared with controls. Neutrophil elastase and histone‐DNA were associated with intensive care admission, body temperature, lung damage, and markers of cardiovascular outcomes, renal failure, and increased interleukin‐6 (IL‐6), IL‐8, and CXCR2. Neutrophil elastase was an independent predictor of the computed tomography score of COVID‐19 lung damage and the number of affected organs, in multivariate analyses. The increased blood concentrations of NE and neutrophil extracellular traps were related to exacerbation of neutrophil stimulation through IL‐8 and CXCR2 increased concentrations and increased serum DAMPs, and to impaired degradation of NETs as a consequence of the dramatic decrease in blood DNase activity. CONCLUSION: Our results point out the key role of neutrophil innate immunity exacerbation in COVID‐19. Neutrophil elastase and DNase could be potential biomarkers and therapeutic targets of severe systemic manifestations of COVID‐19. Coronavirus disease 2019 (COVID-19) produces thromboembolic events and multi-organ manifestations, including heart, liver, and kidneys. 1, 2 They result in part from the excessive involvement of innate immunity 3 and a cytokine storm produced by lymphocyte and macrophage activation. [4] [5] [6] Arguments suggest that neutrophils also play a prominent role in the severe and life-threatening forms of the disease. [6] [7] [8] [9] However, the involvement of neutrophils in systemic and multi-organ outcomes of COVID-19 has deserved insufficient attention. 8 Neutrophils have an arsenal of defensive strategies that include the release of antimicrobial granules and neutrophil elastase (NE), and the formation of neutrophil extracellular traps (NETs). 6, 8 NETs are histone-DNA components of dying neutrophils involved in the host defense against pathogens. 6, 8 A study reported that two markers of NETs, cell-free DNA and myeloperoxidase (MPO)-DNA, were increased in hospitalized COVID-19 patients compared with 30 controls and were correlated with C-reactive protein, D-dimer, lactate dehydrogenase, and absolute neutrophil count. 9 Another study from our group showed that MPO-DNA level is increased in the early phase of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, in ambulatory cases. 10 The homeostasis of circulating NETs is dependent on NE and DNase 1 and DNase 11L3. 6 Excessive NE and NETs in blood produce vascular and tissue lesions in acute viral pneumonia, which resemble those observed in COVID-19 infection. 6, 11, 12 Despite these evidences, whether NE, DNases, and histone-DNA are involved in the multi-visceral manifestations of COVID-19 has not been evaluated to date. The present study is the first one, which studied NE, total DNase activity, and histone-DNA in COVID-19 cases recruited in screening centers, local hospital, and regional hospital in order to evaluate K E Y W O R D S COVID-19, DNase, innate immunity, myeloperoxidase, neutrophil extracellular traps (NETs) Blood levels of neutrophil elastase and histone-DNA are associated with severe and systemic and multi-organ manifestations of COVID-19. Increased blood concentrations of neutrophil elastase and neutrophil extracellular traps are related to exacerbation of neutrophil stimulation through activated IL-8/CXCR2 pathway. Neutrophil elastase and DNase could be potential biomarkers and therapeutic targets of severe systemic manifestations of COVID-19. them according to disease severity and multi-organ manifestations. We found that NE was an independent predictor of the multi-organ injury produced by COVID-19. The release of NE and NETs was related to neutrophil activation by serum damage-associated molecular patterns (DAMPs) and IL-8/CXCR2 pathway. The NICO study (Neutrophil innate Immunity in RT-PCR on nasal swab specimens. The 34 consecutive ambulatory subjects attended the screening center in the first week of the disease, as previously described. 10 We recruited an additional 121 patients hospitalized for COVID-19 in medical departments of local hospitals of the region of Tours (n = 43) and Regional University Hospitals of Marseille and Nancy (n = 78). Among them, 13 were treated in intensive care units. The median of the delay between the onset of symptoms and blood sampling was 7 days (IQR: 4-13) in medical departments and 13 days (IQR: [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] in intensive care units. We reported the clinical characteristics and outcomes of hospitalized patients listed in Table S1 . The scoring of lung damage was evaluated by computed tomography in 5 grades (CT score), as described. 13 The control group included healthy subjects, with no reported contact with infected cases and negative for COVID-19 screening. The sera were used after completion of biochemical testing ordered by the clinician. The remaining samples were stored in the same conditions among groups, at −20°C in the 24 h following blood withdrawal. Routine biochemical markers were assayed in Cobas 8000 analyzers (Roche Diagnostics, Switzerland) and Atellica (Eschborn, Germany). DNase activity was quantified on agarose gel containing 0.13 mg. mL −1 DNA from salmon sperm in a buffer containing 100 mM MES pH 6.5, 20 mM MgCl 2 , 2 mM CaCl 2, and SYBR Safe DNA Gel Stain (Invitrogen, Life Technology) as described. 15, 16 Two microliters of serum was located into wells. Gels were incubated for 24 h at 37°C in a humid chamber. The DNA-SYBR fluorescence was recorded with a fluorescence scanner. To determine whether serum of COVID-19 patients influences cellbound NETs, blood from one healthy donor was mixed (1:1 vol/vol) with patient sera prior to PMA treatment and incubated for 6 h, as described. 14 Isolated neutrophils were resuspended in RPMI 1640, and 1 × 10 5 cells were seeded in 96-well tissue culture plates, as described. 14 Plates were incubated at 37°C to allow cells to adhere. Following stimulation with 100 µl of 0.1 ng/ml PMA for 4 h, wells were incubated with 1 U/ml MNase or DNase 1 (both from Worthington) for 10 min or 10 µl patient or control serum for 6 h, and then 2 mM EDTA was added to stop nuclease activity. The DNA content released in the supernatant was quantified using the Quant-iT PicoGreen® dsDNA Assay Kit (Invitrogen). The amount of released DNA was considered as 100% in unstimulated neutrophils of healthy donors. All quantitative variables are shown as the median and interquartile range (IQR, 25-75th percentile) and qualitative variables as percentages and 95% confidence interval (95% CI). Non-parametric tests were used when data distribution was not normal. Univariate analyses were performed using the chi-squared test or Fisher's exact test for categorical variables and the Mann-Whitney U and the Kruskal-Wallis tests and Spearman's rank correlation for continuous variables. Post hoc pairwise comparisons between subgroups were performed using the Conover test. We subsequently performed receiver operating characteristic (ROC) analysis to look for the optimal thresholds associated with disease outcomes. 17 We subsequently performed receiver operating characteristic (ROC) analysis to look for the optimal threshold associated with disease outcomes, according to DeLong et al. 17 The classification variable used in the ROC analysis was the studied disease outcome. For each ROC analysis, we reported the area under the receiver operating characteristic curve (AUROC) and the associated p-value. The exact binomial method was applied to estimate the 95% confidence intervals (CIs) of the AUROC. The optimal diagnostic cutoff was defined using the Youden index J. Bias-corrected and accelerated (BCa) bootstrap interval after 10,000 iterations for the Youden index and its associated values was performed. 18 Clinical and biological criteria were used to define organ injuries (see the Methods section in this article's Online Repository at www.jacio nline.org). Bias-corrected and accelerated (BCa) bootstrap interval after 10,000 iterations for the Youden index and its associated values were performed. 18 In step #2, using multivariable logistic regression analysis, we assessed whether the ROC-defined threshold defined for elastase (>593 ng/L) was associated with a "number of affected organs ≥2" after accounting for potential confounders. We assessed model discrimination using ROC analysis (AUROC and 95% CI) and model calibration using the Hosmer and Lemeshow goodnessof-fit test and the Nagelkerke R2 statistics. 19 In step #3, we assessed the association between elastase level (> or ≤593 ng/L) and patients' demographics, medical histories, and disease outcomes. A sample size of 7 patients per group was needed to detect an increase ≥200% and 38 patients to detect an increase ≥100% in mean elastase between groups, with 1β at 80% and α at 0.05. Statistical analyses were performed using Table S1, their biological markers, including IL-6, IL-8, CXCR2, TNFα, IL-1β, and HMGB1, are reported in Table S2 , and the characteristics of the 35 healthy controls are reported in Table S3 . The blood levels of NE, MPO-DNA, histone-DNA, and dsDNA of ambulatory and hospitalized COVID-19 patients are reported in Table S4 . They were dramatically higher than those reported in control subjects. In contrast, the global DNase activity was 10-fold lower in COVID-19 cases ( Figure 1A , B). The serum concentration of NE and NET components was not associated with age and sex among groups, and the serum concentration of α1 antitrypsin (AAT), the main blood inhibitor of NE, was normal (Table S2 ). The concentration of NE was significantly higher in hospitalized versus ambulatory cases and patients treated in intensive care versus local hospitals and medical departments of university hospitals ( Figure 1A ). NE was distributed in two clusters of high and lower concentrations in ambulatory cases and patients hospitalized in medical department of regional university hospitals. The clusters with the highest concentrations had similar values than those reported in intensive care units ( Figure 1A ). As observed for NE and NET components, the concentration of dsDNA was higher in patients admitted in intensive care units ( Figure 1B ). In addition, the serum concentration of NE and NET components was associated with the number of affected organs ( Figure 1C ). We studied the associations between elastase, myeloperoxidaseconjugated DNA, and histone-DNA complex and clinical and biological patients' characteristics (Table 1) . We reported significant correlations of NE with histone-DNA, MPO-DNA, and biomarkers of disease severity, SaO2 at hospital admission, leukocytes, neutrophils, neutrophil-to-lymphocyte ratio, LDH, markers of cardiovascular and thrombotic risk, including Troponin-T (cTnT), fibrinogen, and D-dimer, and markers of renal failure, including urea and creatinine (Table 1 and Figure 2) . We also observed a significant association of NE with IL-6, IL-8, and CXCR2, but not with TNFα, IL-1β, and HMBG1 ( Figure 3 ). Significant association of histone-DNA was reported with the computed tomography score (CT score) of lung damage, 13 markers of cardiovascular and thrombotic risk, 13 (Table 1) including cTnT and fibrinogen, markers of renal failure, including urea and creatinine, and markers of inflammation, including C-reactive protein, ferritin, and body temperature ( Figure S1 ). In contrast, MPO-DNA was associated only with leukocytes (p = 0.005) and neutrophils (p = 0.004), and at weaker significance, with D-Dimer (p = 0.045) and fibrinogen (p = 0.047). Total DNase activity was associated with alkaline phosphatase (PAL) and total bilirubin, while dsDNA was associated only with ferritin (Table 1 ). We performed ROC analyses to assess the diagnostic accuracy of NE, MPO-DNA, and histone-DNA for the prediction of diseaserelated outcomes (Table S5 and Forest plot in Figure 4 ). NE had significant thresholds for admission into intensive care units, occurrence of respiratory failure, blood oxygen saturation <85%, and the presence of at least two affected organs ( Figure 4 ). The latter was best predicted with a cutoff at 593 ng/ml of NE. Histone-DNA had significant thresholds for admission into intensive care units, kidney injury, and blood oxygen saturation <85%. MPO-DNA had significant thresholds for heart decompensation, kidney injury, respiratory failure, and blood oxygen saturation <85%. The ROC analyses identified also very significant cutoffs for IL-6, IL-8, and CXCR2 for admission into intensive care units, heart decompensation, kidney injury, and respiratory failure. In contrast, we did not observe these associations with IL-1β and TNFα. In univariate analyses, NE >593 ng/ml was significantly associated with CT score, blood oxygen saturation, respiratory failure, presence of at least two affected organs, and admission into the intensive care unit (Table S6) . We retained chronic kidney disease, diabetes, and hypertension as potential confounders in multivariable analyses (Table S7 ). In the multivariable models that were used to account for the collinearity issue, NE >593 ng/ml was independently associated with CT score and presence of at least two affected organs (Table S8) . The optimal multivariable model had an area under the receiver operating characteristics (AUROC) of 0.876 (95% CI, 0.758-0.950) and a percentage of cases correctly classified of 85%. We performed concordance analyses between cutoffs of NE and cytokines in the prediction of least two affected organs. We reported a 70.4% and 72.7% concordance of NE with CXCR2 and IL-6, respectively (Figure 3 ). We studied cell-bound NETs of control neutrophils incubated with patient sera using flow cytometry. We observed a decreased retention of cell-bound NETs, which reflected an increased release, from cells incubated with patient versus control sera ( Figure 5A ). We further studied the release of dsDNA from control neutrophils produced by patient sera. We observed an increased release of dsDNA from neutrophils incubated with patient versus control sera ( Figure 5B ). The inhibition of NE and other serum serine proteases with 10 μM aprotinin had a weak inhibition effect on dsDNA release ( Figure 5C ). Taken together, these data suggested that the sera from patients increased the release of components of NETs, with a limited role of NE. Our study showed that NE, global DNase activity, and components Histones_DNA aborbance 450 nl Rho = 0.545, P < 0.0001 phase of the infection, as evidenced in hospitalized cases, in particular those recruited in intensive care unit two weeks after the onset of symptoms. Alveolar epithelial cells from lungs infected with influenza virus stimulate NETosis. 21 However, there is a debate on the detrimental versus protective effects of NETs in acute respiratory distress syndrome (ARDS). 22, 23 The citrullinated H3 and cell-free DNA reflect the production of extracellular traps by neutrophils, granulocytes, and monocytes. 23, 24 The dramatic increase in blood concentration of NE reflects more specifically the activation of neutrophils. 24, 25 Of note, NE concentration correlates better with alveolar inflammation than neutrophil count, in acute respiratory distress syndrome. 25, 26 NE, but not histone-DNA and MPO-DNA, was an independent predictor of multi-organ damage in COVID-19 patients. This result reflects the prominent role of NE in the release of NET components and mechanisms of neutrophil innate immunity. 24 NE is dispensed in tissues and blood by degranulation or release with NETs. 24, [27] [28] [29] The induction of ROS by viral infection activates MPO, which then activates the release of NE. 29, 30 The highly significant correlation between NE and histone-DNA and MPO-DNA illustrates the role of NE in NET formation. Upon neutrophil stimulation, NE translocates to the nucleus, where it participates in histone degradation before it releases with the DNA/chromatin material of NETs. 6, 30 Importantly, NE associated with NETs remains active and escapes the endogenous anti-protease activity of AAT. 31 NE can produce tissue damages in lung, heart, liver, vessels, and kidney and exerts prothrombotic effects in viral infection. 6, 26, [31] [32] [33] [34] [35] [36] [37] The degradation of extracellular matrix (ECM) components by NE produces F I G U R E 3 Associations of neutrophil elastase (NE) with cytokines involved in COVID-19 pathological mechanisms. Significant associations of NE were reported with interleukin-6 (IL-6), IL-8, and neutrophil chemokine receptor CXCR2, but not with TNFα. Dotted lines represent the cutoffs reported for multi-organ damage in receiver operating characteristic (ROC) analyses. These cutoffs were used for the concordance analyses. Correlations were assessed by Spearman's rank correlation Forest plot reporting the summary of the receiver operating characteristic (ROC) analyses to assess the diagnostic accuracy of neutrophil elastase (NE), myeloperoxidase (MPO)-conjugated DNA, histone-DNA, cell-free dsDNA, and DNase activity for the prediction of disease-related outcomes. For each biomarker, a ROC analysis was performed using the following classification variables: intensive care unit admission, heart decompensation, liver injury, kidney injury, respiratory failure, blood oxygen saturation <85%, number of affected organs ≥2, and NEWS 2 score ≥5. For each ROC analysis, the summary results were reported using the area under the ROC curve, the 95% confidence interval, and the associated p-value (Table S3) the same lung and vascular injuries as those observed in autopsy specimens of COVID-19 patients. [34] [35] [36] [37] [38] [39] The associations of NE and histone-DNA with SaO 2 at hospital admission and CT score of lung damage of COVID-18 are consistent with their effects in other lung viral infections. 6, 12, 40 Their associations with troponin-T, D-dimer, and fibrinogen suggest their role in the prothrombotic effects reported in COVID-19. [39] [40] [41] The myocardial injury during COVID-19 is not clearly understood. 42-4 4 The mechanisms include direct viral infection, thrombosis, microvascular, and myocardial injury related to reduced oxygen delivery and release of cytokines. 34, 43, 45 The increased cTnT associated with NE could be secondary to coronary thrombosis and myocardial infarction and/or myocarditis. 34, 43, 44 NE and NETs could also contribute to the association of heart injury through systemic effects in kidney and other organs. 2, 45, 46 The associations of NE and histone-DNA with urea and creatinine suggest their involvement in the acute kidney injury reported in about 30% of COVID-19 patients. 33, [47] [48] [49] Our study contributes to a better understanding of pathological mechanisms of COVID-19 by pointing out the key role of the disruption of neutrophil innate immunity during and after viral replication, as summarized in graphical abstract. IL-6, IL-8, and TNFα account among the cytokines predominantly associated with COVID-19 severity. 50 We confirmed this association for IL-6 and IL-8. Increased IL-1β concentrations were positively correlated with disease severity in several studies. 51 However, we did not find any association of IL-1β with outcomes of COVID-19 severity, as previously reported in a recent meta-analysis. 52 These results are consistent with a recent large size study, in which IL-1β was poorly detected and, as a result, had only marginal predictive value of disease severity. 50 as neutrophil-activating chemokine through its binding to CXCR2, which is a major chemokine receptor of neutrophils. 15 Therefore, the dramatic increase in NE in severe COVID-19 may be related to neutrophil activation by the IL-8/CXCR2 pathways. 16 30 For this reason, we think that the association of DNase inhibitors with NE inhibitors should be considered in the treatment of COVID-19. Another therapeutic option to be considered could be the use of inhibitors of CXCR2 to block the neutrophil recruitment and activation. Impairing NE and/or the release of NETs in the early phase of COVID-19 could produce benefits but also risks related to decreasing the host innate immunity. In contrast, we presume that this strategy could decrease the systemic manifestations of COVID-19 in the post-replication phase of the disease. Our study suffered limitations. We could not systematically report all biomarkers in all patients. The recruitment and crosssectional evaluation did not allow us to study the kinetics of NE and NETs by the follow-up of patients. However, we were able to compare the concentration of NE and NETs in ambulatory symptomatic patients recruited during the first week of COVID-19 and patients hospitalized during the second to fourth week of the disease. The multicentric recruitment in local hospitals and in regional university hospitals was a strength of our study for evaluating cases with contrasted disease severity. The exhaustive recording of clinical data allowed us to perform multivariate analysis of the association of NE and NETs with severity and multi-organ damage of COVID-19, after forced adjustment for medical history. In conclusion, our study points out the dramatic increase in NE, DNase activity, and NETs during the first phase of COVID- 19 and their key role in the severity of the acute respiratory distress syndrome and cardiovascular, renal, and inflammatory systemic manifestations in the later step of the disease. They suggest evaluating NE, DNase 1, and NETs as potential therapeutic targets. The NICO study was registered by the Institutional Review Board of Clinical Research (DRCI) of the University Hospital of Nancy (No. Hospital of Nancy. The authors had no conflict of interest to declare. and their immediate family/significant others. A pneumonia outbreak associated with a new coronavirus of probable bat origin Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19 The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020:ciaa270 Neutrophil extracellular traps in immunity and disease Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis Targeting potential drivers of COVID-19: neutrophil extracellular traps Neutrophil extracellular traps in COVID-19 Blood Myeloperoxidase-DNA, a biomarker of early response to SARS-CoV-2 infection? Allergy. 2020 Neutrophil extracellular traps cause airway obstruction during respiratory syncytial virus disease The emerging role of neutrophil extracellular traps in respiratory disease CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19) Endothelial-driven increase in plasma thrombin generation characterising a new hypercoagulable phenotype in acute heart failure NETopathic inflammation in chronic obstructive pulmonary disease and severe asthma COVID-19 hyperinflammation: what about neutrophils? mSphere Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach An introduction to the bootstrap A note on a general definition of the coefficient of determination Respiratory syncytial virus fusion protein promotes TLR-4-dependent neutrophil extracellular trap formation by human neutrophils Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease Understanding the role of neutrophil extracellular traps in patients with severe pneumonia and ARDS Human blood monocytes are able to form extracellular traps Neutral serine proteases of neutrophils Acute lung inflammation: neutrophil elastase versus neutrophils in the bronchoalveolar lavage-neutrophil elastase reflects better inflammatory intensity The role of neutrophil elastase inhibitors in lung diseases Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps Molecular mechanisms of NET formation and degradation revealed by intravital imaging in the liver vasculature The role of neutrophils and neutrophil elastase in pulmonary arterial hypertension Extracellular traps in kidney disease Neutrophil extracellular traps participate in cardiovascular diseases: recent experimental and clinical insights Neutrophil elastase inhibitors and chronic kidney disease Role of the endogenous elastase inhibitor, elafin, in cardiovascular injury: from epithelium to endothelium Neutrophil extracellular traps can serve as platforms for processing and activation of IL-1 family cytokines Neutrophil elastase promotes interleukin-1beta secretion from human coronary endothelium Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19 COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic Myocardial injury and COVID-19: possible mechanisms Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes Coronaviruses pathogenesis, comorbidities and multi-organ damage-A review The heart in COVID19: primary target or secondary bystander? Kidney disease is associated with in-hospital death of patients with COVID-19 Long-term ACE Inhibitor/ ARB use is associated with severe renal dysfunction and acute kidney injury in patients with severe COVID-19: results from a referral center cohort in the northeast of France Kidney disease is associated with in-hospital death of patients with COVID-19 The role of interleukin-6 in monitoring severe case of coronavirus disease 2019 An inflammatory cytokine signature helps predict COVID-19 severity and death Risk factors for severe and critically ill COVID-19 patients: a review The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis Inhibition of Bruton tyrosine kinase in patients with severe COVID-19 COVID-19 gone bad: a new character in the spectrum of the hyperferritinemic syndrome? Mouse deoxyribonuclease I (DNase I): biochemical and immunological characterization, cDNA structure and tissue distribution Caucasian-specific allele in non-synonymous single nucleotide polymorphisms of the gene encoding deoxyribonuclease I-like 3, potentially relevant to autoimmunity, produces an inactive enzyme Evaluation of all nonsynonymous single nucleotide polymorphisms (SNPs) in the genes encoding human deoxyribonuclease I and I-like 3 as a functional SNP potentially implicated in autoimmunity Dnases in health and disease Host DNases prevent vascular occlusion by neutrophil extracellular traps Significance of neutrophil extracellular trap and its markers in the early diagnosis of community-acquired pneumonia in children DAMPs and NETs in Sepsis Elevated serum levels of S100A8/ A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients Inhaled Dornase alfa (Pulmozyme) as a noninvasive treatment of atelectasis in mechanically ventilated patients Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebocontrolled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients Engineered DNAse enzymes and use in therapy Additional supporting information may be found online in the Supporting Information section.